The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet
The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated. Clinical development took longer than expected. Capital became scarce. Several companies downsized or disappeared altogether. Investors who entered during the first wave learned a lesson that every biotech investor eventually faces: scientific breakthroughs rarely follow market timelines. The post The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet appeared first on Microdose.
External link. We are not responsible for the content.
Read more ↗More From Microdose (industry)
Ibogaine’s Momentum Is Real. So Is the Safety Gap Nobody’s Solving.
Recent reporting, has documented a string of serious adverse events at overseas psychedelic clinics such as cardiac d...
Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Ey...
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the...
Latest News
Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness!
Was Carlos Castaneda Among the First Psychedelic Grifters?
Author Carlos Castaneda built a fortune on a fabricated Indigenous lineage. A new biography shows how his blueprint s...
University of Miami’s Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science
Washington, D.C., August 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS)has welcomed the ...
Who Gets to Heal?
A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its executive director asks whether...
Weekly Psychedelic Policy Briefing: August 23, 2026
Oregon's psilocybin program posted its first real-world outcome data this week, just as regulators move on fee increa...
What’s stopping psychedelic therapy in China? 5 Questions with medical ethicist Jennifer Docherty
Docherty discusses her interviews about psychedelic end-of-life care with clinicians in Hong Kong.